Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The primary objective is to test the hypothesis that Quetiapine XR (Extended Release)
monotherapy and adjunctive therapy is effective in the acute treatment of bipolar depression
and comorbid generalized anxiety disorder in patients with bipolar disorder with or without a
substance use disorder. The secondary aim is to generate an estimate of effect size to power
a definitive large-scale, multi-site collaborative R01 and to configure the use of the
primary and secondary outcome measures in the definitive large-scale study.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborators:
AstraZeneca National Alliance for Research on Schizophrenia and Depression